Tachyplesin and polyphemusin
tachyplesin I, II and III (from Tachypleus tridentatus); polyphemusin I and II (from Limulus polyphemus). Polyphemusin II is the parent of the T22 and T140 analogue series, from which the approved CXCR4 antagonist motixafortide descends
1What it is
Horseshoe crabs are among the oldest surviving animal lineages and have no adaptive immune system. They survive in sediment dense with bacteria using an innate immune system built around haemocytes, which on contact with bacterial products degranulate and release a battery of antimicrobial peptides and clotting factors. Tachyplesins were isolated from the Japanese horseshoe crab Tachypleus tridentatus by Nakamura and colleagues in 1988; polyphemusins were isolated shortly afterwards from the Atlantic horseshoe crab Limulus polyphemus. They are closely related — 17 and 18 residues, same disulfide-stabilised hairpin, same heavy positive charge.
They matter for three distinct reasons, and conflating them produces most of the confusion about these peptides.
First, as antimicrobial peptides, they are among the most potent and broadly active natural examples known, and they bind lipopolysaccharide avidly, which makes them of interest in endotoxaemia.
Second, as anticancer leads, tachyplesin I is cytotoxic to tumour cells at achievable concentrations and has been examined as an antitumour agent and in conjugate form.
Third — and this is the genuinely consequential thread — polyphemusin II became a drug scaffold. Researchers found that a modified polyphemusin II, designated T22, had potent anti-HIV activity, and traced this not to membrane disruption but to antagonism of the chemokine receptor CXCR4, which HIV uses as a co-receptor. Systematic downsizing of T22 produced T140, a 14-residue peptide, and further optimisation of that series produced motixafortide, approved in 2023 for mobilising haematopoietic stem cells for collection in multiple myeloma. A horseshoe crab antimicrobial peptide was thus the starting point for an approved CXCR4 antagonist used in bone-marrow transplantation. That is a real and well-documented lineage — and it is not the same thing as saying tachyplesin or polyphemusin is a medicine. The approved drug shares an ancestry, not a pharmacology.
There is a fourth piece of context worth knowing. Horseshoe crab blood is also the source of Limulus amebocyte lysate, the reagent used worldwide to test injectable medicines and medical devices for bacterial . That industry, which bleeds hundreds of thousands of animals annually, has made horseshoe crab conservation a live issue and is driving adoption of the recombinant alternative. Any discussion of horseshoe crab peptides sits inside that context.
2How it's thought to work
3What the research shows
Broad-spectrum antimicrobial activity in vitro
Animal infection models
Endotoxin binding and sepsis models
Antitumour activity
Anti-HIV activity and the CXCR4 lineage
Human data for tachyplesin or polyphemusin themselves
4Reported side effects and interactions
Literature-reported
no human safety data for either parent peptide. The documented liabilities from laboratory and animal work are haemolysis, cytotoxicity to mammalian cells including immune cells at concentrations not far above antimicrobial concentrations, and mast cell degranulation with histamine release reported for cationic peptides generally. Systemic administration in animals is limited by these effects.Community-reported
Community use: essentially none documented. Self-administration would be dangerous and ineffective — these peptides lyse red blood cells and mammalian cells at concentrations close to their antibacterial ones, lose most of their antibacterial potency in blood and in salt, and have no characterised pharmacokinetics in any species. Marketing that invokes the approved CXCR4 antagonist as evidence for a horseshoe crab peptide is conflating a drug with a distant ancestor.Loss of activity in physiological conditions. antimicrobial potency falls substantially at physiological salt concentration, in the presence of serum proteins and divalent cations. This is not a safety issue but it is the reason in-vitro minimum inhibitory concentrations overstate what systemic administration could achieve.
Theoretical. immunogenicity; nephrotoxicity, which is the pattern that has limited other cationic antimicrobial peptides clinically (the polymyxins are the instructive precedent); selection for cross-resistance to host defence peptides, a concern raised about developing any close analogue of human innate immune effectors.
Interactions. none established. Synergy with conventional antibiotics has been reported and is a common research theme for this class.
Markers researchers commonly monitor
No compound-specific markers are established and there is no human administration. The measures that matter in the research literature:
| Marker | Why it's watched |
|---|---|
| Minimum inhibitory and minimum bactericidal concentrations, measured at physiological salt and in serum | the honest version of the antimicrobial readout, and the one that separates publishable potency from plausible potency. |
| Haemolysis assay (percentage lysis of erythrocytes across a concentration range) | the standard counter-screen, and the measure that defines the therapeutic window for this class. A paper reporting antimicrobial potency without it is incomplete. |
| Selectivity index (haemolytic or cytotoxic concentration divided by antimicrobial concentration) | the single number that best predicts whether a cationic antimicrobial peptide can go anywhere. |
| Mammalian cell viability assays | cytotoxicity against relevant human cell lines. |
| Endotoxin neutralisation assays | for the sepsis-related claims. |
| If any cationic antimicrobial peptide were given systemically, renal function would be the dose-limiting monitoring parameter, on the precedent of the polymyxins |
Free for everyone. Safety information is never behind a paywall.
5Research context and safety notes
These are laboratory reagents and discovery scaffolds. The specific constraints: - The therapeutic window is the problem, not the potency. Haemolytic and cytotoxic concentrations sit close to antimicrobial ones. Decades of work on cationic antimicrobial peptides have mostly foundered on exactly this margin, and tachyplesin is not an exception to it. - Potency measured in a tube is not potency in a body. Salt and serum sensitivity means in-vitro minimum inhibitory concentrations substantially overstate achievable activity. Any claim resting on in-vitro numbers should be read with that in mind. - Route. The realistic applications for this class are topical and surface applications, device coatings and food preservation, where systemic exposure and salt effects are limited. That is where the applied literature has gone. - The motixafortide lineage does not transfer. The approved drug is a short, heavily engineered synthetic peptide with a specific receptor mechanism and its own clinical dataset. Shared ancestry confers nothing on the parent peptide. - Source and conservation. Research material is synthesised. Both source species are of conservation concern, T. tridentatus substantially so, and the horseshoe crab bleeding industry that supplies endotoxin-testing reagent is under active pressure to move to recombinant alternatives. No preparation, solvent, concentration or storage guidance is given here.
6Commonly studied alongside
Melittin (#142) as the archetypal membrane-lysing peptide with the same therapeutic-window problem; LL-37 and the human defensins as the mammalian counterparts; polymyxin B and colistin as the cationic antimicrobial peptides that did reach the clinic, and whose nephrotoxicity defines the class's limits; plerixafor as the other approved CXCR4 antagonist, reached by a wholly different chemical route; magainins (frog skin) as the parallel amphibian discovery story.
Informational cross-links. Not stack recommendations.
7Regulatory status by region
| Region | Status (checked —) |
|---|---|
| United States | Neither tachyplesin nor polyphemusin is FDA-approved; research chemicals. Motixafortide, a distant engineered descendant of polyphemusin II, was FDA-approved in 2023 for stem cell mobilisation in multiple myeloma — a separate product with its own dataset |
| European Union | Parent peptides not authorised. Motixafortide status in the EU † |
| United Kingdom | Not licensed |
| Australia | Not approved |
| South Africa | Not registered |
| Sport | Not listed by WADA; S0 would apply in principle to any non-approved substance. No performance application. (Note that CXCR4 antagonists used for stem cell mobilisation touch on haematological manipulation and WADA's M1 blood-doping provisions in principle; this concerns the approved descendant, not these peptides) |
8Open questions
- Can the therapeutic window of a cationic membrane-active peptide be widened enough for systemic use, or is this class permanently limited to topical and surface applications?
- Can salt and serum sensitivity be engineered out without losing activity?
- How far can the CXCR4 story be generalised — are there other specific receptor pharmacologies hidden inside peptides assumed to work only by membrane disruption?
- Does the slow emergence of resistance to membrane-active peptides hold under sustained clinical pressure, and what would resistance to a close analogue of host defence peptides mean for innate immunity?
9References
- 1Nakamura T et al. (1988). Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab (Tachypleus tridentatus). Isolation and chemical structure. J Biol Chem. PubMed
- 2Miyata T et al. (1989). Antimicrobial peptides, isolated from horseshoe crab hemocytes, tachyplesin II, and polyphemusins I and II: chemical structures and biological activity. J Biochem. PubMed · DOI
- 3Nakashima H et al. (1992). Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II). Antimicrob Agents Chemother. PubMed
- 4Tamamura H et al. (1998). A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. PubMed · DOI
- 5Chen Y et al. (2005). Antitumor activity of tachyplesin I and its mechanism [verify exact citation]. PubMed
- 6Crees ZD et al. (2023). Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial (GENESIS). Nat Med. PubMed · DOI
- 7Edwards IA et al. (2016). Contribution of amphipathicity and hydrophobicity to the antimicrobial activity and cytotoxicity of beta-hairpin peptides. ACS Infect Dis. PubMed · DOI
References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.
† Being confirmed by our reviewers against current sources.
10Community
Threads and protocols are visible to members. Joining is free.
Self-reported side effects Phase 2
11Page history
Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.